Published in Gene Therapy Weekly, September 26th, 2002
The grant, entitled "Transactivation of Fetal Hemoglobin Genes for the Treatment of Sickle Cell Disease," was awarded by the National Heart, Lung and Blood Institute and will be paid out over a 4-year period. Investigators at Sangamo and UAB will work collaboratively to target fetal hemoglobin genes with engineered ZFP...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.